PMV Pharmaceuticals Says Interim Phase 2 PYNNACLE Data Show 46% Overall Response Rate In 76 Evaluable TP53 Y220C Ovarian Cancer Patients, Median Duration Of Response 10.0 Months; Plans NDA Submission In Q1 2027
Share
Why It Matters
PMV tested a new cancer medicine on 76 patients and found it helped almost half of them feel better for about 10 months on average. This is good progress that suggests the company might be close to asking the government to approve it for doctors to use.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.